List of Excipients in Branded Drug DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

« Back to Dashboard

Generic Drugs Containing DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Sandoz Inc	dexmedetomidine hydrochloride in 0.9% sodium chloride	0781-3493	SODIUM CHLORIDE
Sandoz Inc	dexmedetomidine hydrochloride in 0.9% sodium chloride	0781-3493	WATER
Sagent Pharmaceuticals	dexmedetomidine hydrochloride	25021-615	SODIUM CHLORIDE
Sagent Pharmaceuticals	dexmedetomidine hydrochloride	25021-615	WATER
Baxter Healthcare Company	dexmedetomidine hydrochloride in 0.9% sodium chloride	43066-555	ACETIC ACID

What are the Most Frequently-Used Excipients in DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?

# Of NDCs	Excipient
1	ACETIC ACID
1	SODIUM ACETATE
4	SODIUM CHLORIDE
4	WATER

Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

Dexmedetomidine hydrochloride in 0.9% sodium chloride is a low-complexity, ready-to-use intravenous formulation with broad hospital utility. The commercial opportunity is driven less by novel excipient protection than by manufacturing reliability, container-closure performance, supply continuity, dose flexibility, and reduced preparation time. The formulation uses dexmedetomidine hydrochloride, sodium chloride, and water for injection, with pH adjustment where applicable. It is generally preservative-free and supplied in premixed bags or ready-to-use containers.

The reference product Precedex was approved by the U.S. Food and Drug Administration in 1999. The active ingredient is an alpha-2 adrenergic receptor agonist used for intensive-care sedation and procedural sedation. Generic competition is established, and the principal commercial barriers are sterile manufacturing, validated aseptic processing, container compatibility, hospital procurement contracts, and reliable supply.

What is the formulation of dexmedetomidine hydrochloride in 0.9% sodium chloride?

The standard premixed formulation contains dexmedetomidine hydrochloride at 4 mcg/mL in 0.9% sodium chloride injection. Commercial presentations have included 200 mcg in 50 mL and 400 mcg in 100 mL containers. The formulation is intended for intravenous infusion and eliminates bedside dilution of a concentrated product.

Formulation attribute	Typical characteristic
Active ingredient	Dexmedetomidine hydrochloride
Active concentration	4 mcg/mL
Diluent	0.9% sodium chloride injection
Common container sizes	50 mL and 100 mL
Route	Intravenous infusion
Preservative	Generally preservative-free
Primary use	ICU and procedural sedation
Sterility requirement	Sterile injectable product
pH control	Product-specific; may use hydrochloric acid or sodium hydroxide
Packaging	Flexible IV bag, vial, or ready-to-use container

The sodium chloride solution provides isotonicity and is familiar to hospital pharmacies and nursing staff. The formulation does not require a novel excipient, lipid system, cosolvent, surfactant, or complex delivery platform.

The FDA label identifies dexmedetomidine hydrochloride and sodium chloride in water for injection as the principal formulation components. The product is supplied as a clear, colorless solution and is intended for controlled intravenous infusion [1].

Why is 0.9% sodium chloride commercially attractive for dexmedetomidine?

0.9% sodium chloride is commercially attractive because it is a standard parenteral vehicle with extensive clinical use, established compendial controls, and broad hospital compatibility. Its use reduces regulatory and technical risk compared with a formulation that depends on an unfamiliar excipient.

The principal commercial advantages are:

1. Ready-to-use administration without pharmacy dilution.
2. Lower medication-preparation workload.
3. Reduced risk of dilution and concentration errors.
4. Compatibility with standard infusion pumps and hospital protocols.
5. Familiar procurement and storage requirements.
6. A straightforward regulatory pathway for generic or line-extension products.

The main limitation is volume. A 50 mL or 100 mL saline bag can create unnecessary fluid administration for patients requiring prolonged sedation or fluid restriction. That limitation creates an opportunity for higher-concentration presentations, concentrated vials, and lower-volume ready-to-administer systems.

What excipient strategy is appropriate for this formulation?

The strongest excipient strategy is a minimal-excipient design centered on sodium chloride, pH control, and container compatibility. A sponsor should avoid unnecessary formulation changes unless they solve a documented clinical or manufacturing problem.

Sodium chloride as the primary excipient

Sodium chloride provides the vehicle and contributes to isotonicity. Its use supports:

• Established injectable-drug safety history.
• Simple composition disclosure.
• Straightforward raw-material qualification.
• Familiar osmolality targets.
• Broad clinical acceptance.
• Lower risk of excipient-related regulatory questions.

The target osmolality should remain suitable for peripheral or central intravenous administration under the applicable product labeling. Excessive osmolality can create tolerability and administration concerns.

pH adjustment

Dexmedetomidine hydrochloride is supplied as a salt, and the final product requires control of pH throughout shelf life. Hydrochloric acid and sodium hydroxide are conventional pH-adjusting agents for sterile injectable products. The commercial objective is not to introduce a new buffer system unless stability data demonstrate a need.

A buffer may affect:

• Chemical degradation.
• Container interaction.
• Extractables and leachables.
• Osmolality.
• Freeze-thaw behavior.
• Compatibility with infusion lines.

A buffered product could create differentiation, but it also increases development and regulatory burden. For a generic 0.9% sodium chloride product, a simple pH-adjusted saline system is generally the lower-risk path.

Preservative-free design

A preservative-free formulation is preferred for intravenous use, particularly in ICU and procedural settings. It avoids benzyl alcohol, parabens, and other antimicrobial preservatives that may raise concerns in neonates, critically ill patients, or patients receiving repeated infusions.

Antioxidants and chelators

Routine use of antioxidants or chelating agents should be avoided unless required by degradation data. These excipients can alter the regulatory profile and complicate compatibility assessments. The preferred control strategy is protection from light where necessary, oxygen management, raw-material control, and validated sterilization and filling processes.

What formulation risks affect dexmedetomidine hydrochloride in saline?

The key technical risks are chemical stability, adsorption, particulate formation, container interaction, and infusion-set compatibility.

Chemical stability

A development program should characterize:

• Assay and related substances.
• pH drift.
• Color change.
• Visible and subvisible particles.
• Osmolality.
• Sterility and bacterial endotoxins.
• Stability after simulated transport.
• In-use stability after container opening or spike insertion.

Dexmedetomidine concentrations are low relative to many injectable drugs. Low-dose products require sensitive analytical methods and tight control of content uniformity, adsorption, and sample handling.

Adsorption and surface interaction

Adsorption to polymeric tubing, infusion bags, filters, or syringes can reduce delivered dose. The risk depends on:

• Polymer type.
• Surface treatment.
• Contact time.
• Flow rate.
• Drug concentration.
• Temperature.
• Presence of other infused drugs.

A commercial product should be evaluated in the intended bag material and with commonly used administration sets. A low-sorption container can support a stronger hospital value proposition if the data are clinically relevant and permitted in labeling.

Container-closure selection

Flexible polyolefin bags are commercially attractive because they are lightweight and compatible with hospital distribution systems. Glass and rigid polymer containers can provide different oxygen and moisture-barrier characteristics but may increase breakage, weight, or logistics costs.

The container system should be assessed for:

• Extractables and leachables.
• Seal integrity.
• Port performance.
• Light transmission.
• Overwrap requirements.
• Shipping vibration and compression.
• Compatibility with automated dispensing systems.

Terminal sterilization versus aseptic processing

The formulation and container must support the selected sterilization strategy. Aseptic processing may be necessary where terminal sterilization affects drug stability or container integrity. A terminally sterilized product can offer manufacturing and sterility-assurance advantages if the formulation tolerates the process.

The choice affects capital requirements, batch release, validation burden, and supply-chain resilience.

What FDA regulatory status applies to dexmedetomidine hydrochloride injection?

Precedex is an FDA-approved reference product. The original approval established dexmedetomidine hydrochloride injection for sedation of initially intubated and mechanically ventilated patients in an intensive-care setting and for procedural sedation in non-intubated patients [1].

Generic manufacturers can generally pursue an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. A conventional injectable solution in the same active ingredient, concentration, route, dosage form, and vehicle may avoid the clinical development burden associated with a new formulation.

Regulatory review focuses on:

• Pharmaceutical equivalence.
• Bioequivalence requirements applicable to injectable products.
• Sterility.
• Endotoxin control.
• Extractables and leachables.
• Stability.
• Container-closure integrity.
• Manufacturing process validation.
• Labeling and administration instructions.

A product with a materially different concentration, container, delivery system, or clinical indication may require a separate regulatory strategy.

What is the Orange Book and patent status of Precedex and generic dexmedetomidine?

Dexmedetomidine is a mature small-molecule product with generic competition. The original active-ingredient and product exclusivity periods have expired. The principal U.S. market pathway is therefore ANDA competition rather than protected brand exclusivity.

Issue	Commercial position
Reference product	Precedex
FDA approval	1999
Active ingredient	Dexmedetomidine hydrochloride
Core composition	Dexmedetomidine in injectable aqueous vehicle
U.S. chemical exclusivity	Expired
U.S. generic pathway	ANDA
Paragraph IV relevance	Mainly for any later-listed, unexpired patent claims
Current competitive issue	Manufacturing, price, supply, and procurement access
Biosimilar pathway	Not applicable

The original dexmedetomidine patent estate included U.S. patents covering the compound and related pharmaceutical uses. Those foundational rights have expired. The Orange Book should be reviewed for any current listed patents associated with a particular reference product or later formulation, but a standard dexmedetomidine hydrochloride solution in 0.9% sodium chloride is primarily exposed to conventional generic competition [2, 3].

How relevant are Paragraph IV challenges?

Paragraph IV litigation is less important for the basic premixed saline product than it was during the original generic-entry period. A Paragraph IV certification becomes commercially significant only when an ANDA applicant targets an unexpired listed patent. For a mature injectable product, the greater risk is often paragraph III certification, patent listing disputes, or no-patent-certification filing rather than a new foundational patent challenge.

Potential dispute areas include:

• Concentration-specific claims.
• Ready-to-use bag claims.
• Container or packaging claims.
• Stability claims.
• New method-of-use claims.
• Pediatric or procedural-sedation indications.

What patents protect dexmedetomidine hydrochloride formulations?

The strongest historical patent protection covered the dexmedetomidine molecule and its pharmacological use rather than the simple saline vehicle. A conventional aqueous formulation using 0.9% sodium chloride is difficult to protect broadly with composition claims because saline is a standard injectable excipient.

Potentially protectable subject matter includes:

• Narrow concentration ranges.
• Specific pH ranges.
• Stability-improving excipient combinations.
• Low-sorption container systems.
• Premixed bag configurations.
• Specific infusion protocols.
• Ready-to-administer packaging.
• Manufacturing or sterilization methods.
• Particular pediatric or procedural-sedation regimens.

These claims face enablement, written-description, obviousness, and anticipation risks. A formulation patent is more commercially defensible when it links a defined composition to measurable performance, such as improved stability, reduced adsorption, reduced particulate formation, or longer in-use shelf life.

How strong is the patent estate for dexmedetomidine in 0.9% sodium chloride?

The patent estate is weak for a basic saline formulation and stronger for differentiated delivery or manufacturing technology.

Patent category	Relative strength for standard saline product
Original chemical compound	Expired foundational protection
General injectable composition	Low, because the formulation is conventional
0.9% sodium chloride vehicle	Low
Specific pH and stability range	Moderate if supported by unexpected results
Container-closure system	Moderate
Low-sorption delivery system	Moderate to strong if technically demonstrated
Manufacturing process	Moderate, subject to process-around risk
Method of use	Narrower and indication-dependent
Ready-to-use packaging	Usually limited unless technically specific

The strongest protection is likely to come from a combined product architecture: a defined concentration, validated container, demonstrated stability profile, low-sorption administration system, and operational advantage in hospital use.

What commercial opportunities exist beyond the standard 4 mcg/mL product?

The largest opportunities involve reducing preparation steps, supporting fluid-restricted patients, and improving procurement reliability.

Higher-concentration and lower-volume products

A higher-concentration presentation could reduce fluid burden. Examples may include concentrated vials for pharmacy dilution or ready-to-administer products with a higher dexmedetomidine concentration. These products would require careful evaluation of dosing errors, pump programming, labeling, and medication safety.

Ready-to-use syringes

Pre-filled syringes could support procedural sedation, emergency use, transport, and operating-room workflows. The commercial value would depend on:

• Syringe stability.
• Dose accuracy.
• Device compatibility.
• Needleless-access compatibility.
• Human-factors validation.
• Unit cost relative to bags.

Small-volume bags

A 25 mL or other lower-volume bag could target pediatric care, procedural sedation, and patients requiring fluid restriction. The product would need a clear administration advantage over the existing 50 mL and 100 mL presentations.

Premixed dual-use portfolio

A manufacturer could offer:

• Standard 4 mcg/mL bags for ICU protocols.
• Smaller bags for procedural sedation.
• Concentrated vials for pharmacy-controlled preparation.
• Pre-filled syringes for short procedures.
• Alternative container materials for automated dispensing systems.

Portfolio breadth can increase formulary coverage but adds inventory complexity. The strongest commercial model is usually a limited number of presentations mapped to distinct clinical workflows.

Which companies are competing in dexmedetomidine injection?

Competition includes the originator manufacturer and multiple generic injectable manufacturers. Product availability has included branded and generic offerings from companies such as Hospira, Pfizer, Fresenius Kabi, Hikma, Sandoz, and other approved ANDA holders, depending on market and time period.

The competitive basis is not primarily molecular differentiation. It is:

• Contract pricing.
• National wholesaler coverage.
• Back-order performance.
• Manufacturing redundancy.
• Bag and vial availability.
• Packaging quality.
• Hospital medication-use efficiency.
• Regulatory and pharmacovigilance execution.

A new entrant must demonstrate dependable supply. A lower list price alone is unlikely to displace an incumbent if hospitals face substitution, shortage, or quality risks.

What litigation and settlement risks affect dexmedetomidine?

The mature product has limited expected litigation exposure for the basic saline formulation. Risk increases when a sponsor introduces a new formulation or indication that may overlap with later patents.

Potential disputes include:

• ANDA patent litigation.
• Orange Book listing challenges.
• Patent-term calculations.
• Labeling carve-outs for method-of-use claims.
• Trade dress and packaging disputes.
• Manufacturing process claims.
• Contract-manufacturing confidentiality and technology-transfer disputes.

Settlement agreements can delay generic launch or define licensed entry dates, but their commercial significance depends on the specific patent claims and settlement terms. A standard saline product without an active patent barrier is more likely to face price competition than delayed entry.

How does dexmedetomidine in saline compare with competing sedatives?

Dexmedetomidine competes clinically with propofol, midazolam, and opioid-based sedation regimens. Its commercial differentiation is linked to sedation characteristics and workflow, not excipient novelty.

Product	Common formulation issue	Commercial comparison
Dexmedetomidine in 0.9% sodium chloride	Low-concentration premix and fluid volume	Ready-to-use, but unit cost can be higher
Propofol injection	Lipid emulsion handling and infection-control requirements	Different storage and administration controls
Midazolam injection	Often requires bedside dosing or dilution	Lower-cost generic alternative
Opioid infusion products	Controlled-substance management	Used for analgesia and sedation, with different safety profile

Dexmedetomidine products can command workflow value when they reduce preparation time or support protocolized sedation. Hospitals will compare acquisition cost, nursing labor, infusion volume, adverse-event management, and supply reliability.

What manufacturing and intellectual-property barriers exist?

The primary barriers are operational rather than patent-based. A sponsor needs validated sterile manufacturing, reliable dexmedetomidine hydrochloride API supply, and a container system that maintains quality through shelf life.

Key barriers include:

• API impurity control.
• Low-dose assay accuracy.
• Aseptic filling capability.
• Sterility assurance.
• Container-closure integrity.
• Extractables and leachables testing.
• Adsorption studies.
• Particulate control.
• Stability-indicating analytical methods.
• Commercial-scale process reproducibility.
• Multi-site supply planning.

API sourcing can create a material risk because a sterile injectable product is exposed to both drug-substance and drug-product disruptions. Dual sourcing, qualified alternate manufacturing sites, and sufficient safety stock can be more valuable than narrow formulation patent claims.

What generic launch scenarios exist for dexmedetomidine saline products?

The most likely launch scenarios are:

1. Price-led standard bag entry using the established 4 mcg/mL concentration.
2. Hospital-contract entry based on supply reliability and shortage mitigation.
3. Lower-volume product entry for pediatric and fluid-restricted patients.
4. Pre-filled syringe entry for procedural and emergency workflows.
5. Concentrated vial entry for pharmacy-controlled dilution.
6. Contract-manufacturing or licensing entry using an existing sterile injectable platform.

The first scenario has the lowest technical risk but the highest price pressure. The lower-volume and pre-filled formats offer greater differentiation but require more device, stability, and human-factors work.

What licensing deals could create value?

Licensing opportunities are most credible in four areas:

• Dexmedetomidine API supply.
• Ready-to-use sterile filling capacity.
• Low-sorption container or administration technology.
• Regional commercialization rights.

A license for the basic 0.9% sodium chloride formulation is unlikely to create substantial value unless it includes manufacturing capacity, regulatory approvals, hospital contracts, or protected delivery technology. The strongest transaction structure would link a formulation or device right to guaranteed sterile supply and defined geographic commercialization rights.

What is the revenue exposure and market outlook?

Revenue exposure is tied to hospital injectable procurement rather than retail prescribing. The product is used in ICU, operating-room, procedural, pediatric, and transport settings. Demand can increase when hospitals standardize sedation protocols or experience shortages of competing sedatives.

The standard formulation faces price erosion from generic competition. Revenue protection depends on:

• Maintaining high service levels.
• Winning group purchasing organization contracts.
• Offering multiple container sizes.
• Avoiding shortages and recalls.
• Supporting automated dispensing and pharmacy workflows.
• Demonstrating reduced preparation burden.

A differentiated product can preserve pricing if it reduces fluid load, improves administration efficiency, or fills a shortage-sensitive segment.

Key Takeaways

• Dexmedetomidine hydrochloride in 0.9% sodium chloride is a mature, low-complexity sterile injectable formulation.
• Sodium chloride is the preferred primary excipient because it is familiar, isotonic, inexpensive, and regulatorily established.
• The standard 4 mcg/mL premix has limited composition-patent potential.
• Foundational dexmedetomidine compound protection and original exclusivity have expired.
• Generic competition is established, making supply reliability and hospital contracting central commercial factors.
• The strongest innovation opportunities are lower-volume bags, higher-concentration formats, pre-filled syringes, and low-sorption container systems.
• Manufacturing, sterility assurance, container compatibility, and API supply are more important barriers than basic formulation patents.
• A licensing transaction is most valuable when it includes sterile capacity, regulatory approvals, hospital access, or differentiated delivery technology.

Frequently Asked Questions

Can dexmedetomidine hydrochloride be formulated in 5% dextrose instead of 0.9% sodium chloride?

Yes. Dexmedetomidine injection labeling identifies compatible diluents that may include 0.9% sodium chloride and 5% dextrose, subject to product-specific instructions and stability data [1]. A dextrose formulation may support selected clinical workflows but does not automatically create meaningful patent differentiation.

Does a saline premix require a new clinical trial?

A conventional generic injectable may generally proceed through the ANDA pathway without a full efficacy trial if it meets applicable pharmaceutical equivalence and bioequivalence requirements. A new concentration, device, indication, or materially different formulation may require a different regulatory strategy.

Is dexmedetomidine hydrochloride a biologic?

No. Dexmedetomidine hydrochloride is a chemically synthesized small molecule. Biosimilar pathways do not apply. Generic competition proceeds through small-molecule abbreviated applications.

Can sodium chloride concentration be adjusted to reduce fluid load?

Changing the sodium chloride vehicle or increasing dexmedetomidine concentration may reduce administered volume, but it requires formulation, safety, labeling, and regulatory evaluation. The resulting product may no longer be a straightforward equivalent to the standard 4 mcg/mL saline premix.

What is the main commercial weakness of the standard saline formulation?

The main weakness is limited differentiation. Because the vehicle and formulation are conventional, manufacturers compete primarily through price, supply continuity, packaging, availability, and hospital contracting.

References

1. U.S. Food and Drug Administration. (2023). Precedex (dexmedetomidine hydrochloride) injection, for intravenous use: Prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/